Gilead Sciences, Inc. (GIS.DE) XETRA
110.30
-2.18(-1.94%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Gilead Sciences, Inc.
Address
333 Lakeside Drive
Foster City, CA 94404
United States of America (the)
Phone
650 574 3000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
17600
First IPO Date
January 03, 2000
Key Executives
| Name | Title | Pay | Year Born |
| Daniel O'Day | Chairman & Chief Executive Officer | 7.47M | 1965 |
| Andrew D. Dickinson | Executive VP & CFO | 2.7M | 1970 |
| Johanna Mercier | Chief Commercial & Corporate Affairs Officer | 2.95M | 1970 |
| Dietmar Berger | Chief Medical Officer | 5.09M | 1969 |
| Flavius Martin | Executive Vice President of Research | 0 | N/A |
| Linda Slanec Higgins | Senior Vice President of Research, Innovation & Portfolio | 0 | 1962 |
| Stacey Y. Ma | Executive VP of Pharmaceutical Development & Manufacturing | 0 | 1971 |
| Bernard Fine | Vice President of Oncology & Franchise Head of Early Development | 0 | N/A |
| Erin Burkhart | Senior VP, Controller & Chief Accounting Officer | 0 | 1979 |
| Jacquie Ross | Senior Vice President of Treasury and Investor Relations | 0 | N/A |
| Janet Dorling | Senior Vice President of Intercontinental Region & Global Patient Solutions | 0 | 1975 |
| Jyoti K. Mehra | Executive Vice President of Human Resources | 0 | 1977 |
| Keeley Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary | 0 | 1975 |
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
